Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis ; volume:8 ; number:3 ; day:4 ; month:3 ; year:2024 ; pages:445-457 ; date:5.2024
PharmacoEconomics - open ; 8, Heft 3 (4.3.2024), 445-457, 5.2024
- Creator
-
Bührer, Christian
Paling, Thomas
Gale, Richard
Paulo, Tatiana
Bagijn, Marloes
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s41669-023-00465-4
- URN
-
urn:nbn:de:101:1-2407112105338.369027652911
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bührer, Christian
- Paling, Thomas
- Gale, Richard
- Paulo, Tatiana
- Bagijn, Marloes
- SpringerLink (Online service)
Other Objects (12)
Summary of Research: Cost‑Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review
Burden of Disease Study of Patients with Diabetic Macular Oedema in Spain
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists
Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial
Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up
Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
Summary of Research: Cost‑Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review
Burden of Disease Study of Patients with Diabetic Macular Oedema in Spain
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists
Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial
Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up
Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
Summary of Research: Cost‑Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review
Burden of Disease Study of Patients with Diabetic Macular Oedema in Spain
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists
Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial
Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up